Cargando…
Latest Evidence on Sulfonylureas: What’s New?
This review addresses the question of the cardiovascular (CV) safety of sulfonylureas (SUs) in patients with type 2 diabetes mellitus (T2DM) when directly tested against comparator agents in CV outcome trials. Presented at a recent symposium entitled “SUs in the treatment of T2DM: a fresh look and n...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261305/ https://www.ncbi.nlm.nih.gov/pubmed/32323156 http://dx.doi.org/10.1007/s13300-020-00812-2 |